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Extracorporeal enzymatic heparin removal: Use in a sheep dialysis
model. Extracorporeal medical devices such as the hemodialyzer rely
on systemic heparinization to prevent thrombus formation. Heparin,
however, can lead to serious hemorrhagic complications. A blood filter
containing immobilized heparinase, a heparin specific enzyme, was
used to degrade heparin into small fragments which have significantly
less anticoagulant activity than the parent compound. The heparinase
filter was tested in the extracorporeal circuit during the hemodialysis of
adult sheep. At a blood flow of 200 mI/mm, the clearance of heparin
varied from 50 to 70 mI/mm (N = 16) depending on the amount of
immobilized heparinase in the ifiter. Hemolysis was insignificant as
measured by the animals' red cell counts, hematocrit, total hemoglobin
and a plasma—free hemoglobin value of 89 33 mg/dl (N 16) (less
than 1% of the total hemoglobin). The white cell counts dropped to 47
7% (N = 16) of the initial value at 20 minutes and rebounded to 72
10% (N = 16) after one hour. The platelet counts decreased to 55 8%(N = 16) of the initial value after one hour. No change in heparin
clearance was observed when reactors were used repeatedly in adult
sheep over a 10 week period. The red cell counts, white cell counts,
platelet counts, total hemoglobin and hematocrit did not change after 10
weeks of exposure to the device. These results suggest that with further
study, heparinase may be useful in removing heparin used to anticoa-
gulate blood in extracorporeal circuits.
Hemodialysis requires heparin to prevent clotting of the
extracorporeal circuit. This systemic heparinization leads to a
high incidence of hemorrhagic complications [1, 2]. A number
of alternatives have been explored to alleviate the problems
associated with the resultant plasma heparin levels. The neu-
tralization of heparin with protamine sulfate before the blood is
returned to the patient is the most common method [3]. Pro-
tamine, however, causes hypotension as well as being an
anticoagulant itself, and its anti-hepann effect is quite variable
[3—5].
Some investigators have used low dose heparin or low
molecular weight heparins to minimize the amount of anticoag-
ulation to which the patient is subjected [2, 6, 7]. Prostacyclin
has been tried as a hepann substitute, however, it can cause
hypotension [8—to]. A great deal of research has been devoted
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to the creation of new blood—compatible materials or to improv-
ing the biocompatibility of existing materials by the immobili-
zation of heparin [11—13]. Hemodialysis techniques without
anticoagulation, such as high flow, heparin-.free saline—free
dialysis and saline flush dialysis, have also been attempted [14,
15]. Although each of these developments has led to some
improvements, control of blood hepann levels remains a seri-
ous problem.
A new approach which would allow on—demand removal of
heparin from the patient's bloodstream has been proposed [16].
Heparin is eliminated from the blood by placing a filter contain-
ing immobilized heparinase in the extracorporeal device.
Heparinase is isolated from Flavobacterium heparinum and
degrades heparin into non-toxic, low molecular weight frag-
ments that have much less anticoagulant activity than the
parent compound heparin [17, 18]. Heparinase was covalently
immobilized to a solid support to prevent the direct in vivo
introduction of the enzyme as well as to enhance its stability
[19]. In a study involving over 20 different supports, an agarose
gel activated with cyanogen bromide afforded the greatest
recovery of enzymatic activity [19] and was selected for the
current study. The gel was placed in a modified blood filter
through which the blood is passed and the heparin was de-
graded. A regional heparinization procedure was used to main-
tain a high activity of heparin in the extracorporeal circuit while
having a much lower level in the animal. The heparinase reactor
was used to eliminate the additional heparin after it had served
its purpose in the extracorporeal device and before the blood
was returned to the animal.
The present study was concerned with the initial develop-
ment and testing of the heparinase reactor for hemodialysis or
other applications using extracorporeal blood perfusions. The
work was conducted in two stages; the first dealt with the
development of the reactor and the second dealt with the testing
of the device at conditions simulating hemodialysis.
The heparinase filter was tested in sheep since the animal's
blood volume is comparable to that of man's and thus a filter
whose capacity would be of clinical usefulness can be tested.
Uremic sheep were not used since they can be maintained
chronically only with great difficulty [20]. Furthermore, hemo-
dialysis of sheep with normal renal function requires signifi-
cantly more heparin for anticoagulation, thus, providing a more
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difficult clinical test. Both the clearance of heparin and the
hemocompatibility of the device were examined.
Methods
Heparinase preparation
F/a vobacterium heparinum was grown according to the pro-
cedure of Galliher et al [21]. The cells were homogenized and
heparinase was purified from the homogenate using hydroxyl-
apatite chromatography and QAE-Sephadex chromatography
[22]. This heparinase preparation was immobilized directly to
cyanogen bromide activated agarose as discussed below. Pro-
tein concentrations were determined by the method of Bradford
[23].
The activity of soluble and immobilized heparinase in buffer
was measured by following the appearance of heparin degrada-
tion products at 232 nm [19]. One unit of heparinase activity
was defined as the amount of enzyme that fully degrades 1 mg
of heparin per hour.
Preparation of crosslinked agarose
Agarose (500 ml, Bio-Rad Laboratories, Rockville Center,
New York, USA) was washed with distilled water to remove
preservatives and then resuspended in 500 ml of 1 M sodium
hydroxide. The mixture was heated to 50°C and 10 ml of 2,3,
dibromopropanol (Aldrich Chemicals, Milwaukee, Wisconsin,
USA) was added. The reaction was continued at 50°C for one
hour and after that an additional 10 ml of the crosslinking agent
was added. The reaction continued for an additional hour, and
the gel was removed by filtration on a sintered glass funnel. The
gel was resuspended in 500 ml of 1 M sodium hydroxide and the
above procedure was repeated. The agarose was then filtered
and washed with 20 to 25 liters of distilled water.
Immobilization of heparinase
Agarose was activated with cyanogen bromide using a mod-
ified procedure of March, Parikh and Cuatrecasas [24]. The
crosslinked agarose (100 ml) was resuspended in 100 ml of
distilled water and 200 ml of 2 M sodium carbonate and chilled
to 4°C. To the agarose suspension, 40 ml of cyanogen bromide
in acetonitrile was added (1 g of CNBr/ml of acetonitrile). The
mixture was vigorously agitated in a fume hood for five min-
utes. The reaction mixture was quickly filtered and washed with
4 x 500 ml of chilled distilled water, 2 x 500 ml of chilled 1 mM
HC1 and 2 x 500 ml of 0.1 M NaHCO3, 0.5 M NaCl(pH 8.3). The
beads were suctioned dry and mixed immediately with 200 ml of
the heparinase preparation and the mixture was placed on an
orbital shaker (Boekel, West Germany). The coupling pro-
ceeded for 12 hours at 4°C.
After 24 hours, the suspension was filtered, and resuspended
in 300 ml of NaHCO3 buffer (0.1 M, pH 8.3) containing 0.5 M
NaCl and 0.2 M lysine (pH 8.3) overnight at 4°C for 24 hours.
The beads were washed to remove non-covalently attached
protein with 3 x 250 ml of chilled buffer containing 0.25 M
NaH2PO4, 0.5 M NaC1 (pH 7.0), and then with 3 x 250 ml of
chilled buffer containing 0.0725 M NaH2PO4 and 0.125 M NaCI,
(pH 7.0).
The fraction of heparinase activity retained after covalent
immobilization was computed as the ratio of the activity of the
immobilized heparinase to the difference in activity between the
Fig. 1A. The heparinase reactor which consists of a 250 ml blood filter
which has been modWed to include a recirculation line inserted at the
bottom of the filter. The recirculation line is connected to a peristaltic
pump which maintains the contents of the filter well mixed. The inlet
and the outlet to the reactor are as shown in the figure. B. An enlarged
cutaway of the inside of the heparinase filter. An internal 25 m cutoff
polyester mesh restrains the immobilized enzyme particles from exiting
the reactor. Each segment of the recirculation line within the reactor
contained six pairs of holes 2.5 mm in diameter.
initial and final heparinase solutions. Heat inactivated immobi-
lized heparinase was prepared by incubating the enzyme at 80°C
for three hours.
Measurement of gel volumes and particle diameters
All agarose volumes were measured by centrifuging the gel
for five minutes at 2000 g in graduated tubes. The diameters of
the agarose beads were measured using light microscopy. Slides
with dilute samples of beads were photographed with a light
microscope (American Optics A-l 10) to which a Polaroid SX-70
land camera had been mounted. A 1 mm calibration slide from
Bausch and Lomb was used to correlate the lengths measured
from the photographs with actual bead diameters.
Reactor fabrication
A 250 ml blood filter (Model AF-lO, American Hospital
Supplies, Irvine, California, USA) was used as the reactor
vessel (Fig. 1). The housing is constructed from polycarbonate
and contains an internal 25 sm cutoff polyester mesh. The mesh
restrained the immobilized enzyme particles from exiting the
reactor.
The filter was modified to include a recirculation line which
was connected to a secondary peristaltic pump as shown in
Figure 1. Each segment of the recirculation line within the
reactor contained six pairs of holes 2.5 mm in diameter. This
served to direct the fluid in multiple directions and to enhance
mixing within the device.
Two 3/4-inch holes were drilled on either side of the outlet
port of the blood filter and the ends of a 20 inch silastic tube
(Cole Palmer #6418) were inserted. The two holes were sealed
A
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Fig. 2. A schematic of the complete extracorporeal circuit. Heparin is
infused directly into the arterial tubing just prior to the hemodialyzer.
Blood samples are drawn at points A, B, and C which are representative
of the blood in the animal, before the reactor and after the reactor,
respectively.
under vacuum with Silicone RTV gel and allowed to set
overnight.
Reactor priming and dialyzer preparation
A 100 liter Travenol dialysis unit with a negative pressure
converter was filled with one liter of Diasol concentrate (Travenol
Laboratories, Deerfield, Illinois, USA) diluted with 100 liters of
distified water. The hollow fiber dialyzer (Model 1500, Travenol)
was soaked at a pressure of —200 mm Hg for ten minutes with
the dialysate which had been preheated to 38°C. Physiological
saline containing heparin (2 USP' U/ml, Elkins.-Sinn Cherry
Hill, New Jersey, USA) was pumped into the blood side of the
dialyzer and the saline was recirculated through the dialyzer for
ten minutes to remove all the air.
The reactor was vented as hepannized physiological saline (2
USP U/mi) was pumped at 150 mllmin into the empty device.
After the air had been purged, the immobilized heparinase
slurry was pumped into the reactor at 75 mi/mm. The reactor
was then connected to the dialyzer outlet as described below.
Animal preparation
Two weeks prior to experimentation, Thomas shunts were
anastomosed to the carotid artery and the jugular vein of
healthy adult female sheep (60 to 70 kg). A total of 24 animals
were utilized for the design and testing of the reactor. Blood
flows in the range 120 to 250 ml/min were attained with no
detectable side effects to the animal. The number of experi-
ments performed on each animal varied from 3 to 16 depending
on the patency of the animal's shunt.
The extracorporeal circuit was a closed loop containing the
dialyzer, the heparinase reactor and the animal, Figure 2. The
blood was pumped from the carotid shunt, through an arterial
line (ID 0.25 in., 8 ft. long), a bubble trap, the dialyzer, the
reactor, and back into the animal through a venous line (ID 0.25
in., 6 ft. long) equipped with a thrombus and bubble trap.
For the duration of the experiment, the animal was secured to
the sideboard of a wooden platform (6 ft. x 2.5 ft. X 6 ft.) via
The abbreviations used in this paper: aPTT, activated partial
thromboplastin time, ID, inner diameter, EDTA, ethienediaminetetra-
acetate, SD, standard deviation, USP, United States Pharmacopeia
two belt straps. The shunt area was cleansed with betadine and
the shunts were clamped with hemostats and pulled apart. The
shunts were fitted immediately with syringes to prevent con-
tamination and clotting. An intravenous injection of heparin
(3000 USP U) was administered through the venous shunt to
systemically heparinize the animal.
The arterial line was connected directly to the animal's
arterial shunt, the hemostat removed and the blood pump
started. The heparinized saline used to prime the system was
pumped directly into the animal to compensate for the blood
volume in the circuit.
A regional heparinization scheme was used to maintain the
concentration of heparin in the extracorporeal circuit higher
than in the animal. Heparin was continuously infused into the
arterial line at 10000 or 18000 USP U/hr using a syringe infusion
pump (Harvard Co., Millis, Massachusetts, USA). The higher
infusion rate was used when the dialyzer was included in the
extracorporeal circuit. These heparin dosages correspond to
200 to 300 U/kg which are greater than the 100 U/kg commonly
used for hemodialysis. These larger doses of heparin were
required to prevent the circuit from clotting since sheep have
platelet counts in the range 400000 to 800000/mm3 [25]. The
heparinized blood then passed through the dialyzer, the hepa-
rinase reactor, and back to the sheep via the venous line.
The pressure drop across the reactor was measured using two
strain gauge pressure transducers (Tyco Co.) positioned before
and after the reactor.
Measurement of plasma heparin
Blood sampling began after all the priming saline had been
washed out of the circuit. This was attained after the animal had
been connected to the extracorporeal circuit for twenty min-
utes. The length of each experiment was one hour, and thus
heparin clearance data was acquired for 40 minutes of the one
hour experiment.
Blood samples for heparin monitoring were taken in duplicate
from two injection ports, before and after the reactor (Points B
and C, Fig. 2). Whole blood samples were drawn with 20 gauge
needles into disposable 3 ml polypropylene syringes containing
300 pi 3.8% sodium citrate. Sheep plasma was prepared by
centrifuging the samples at 3000 g at 4°C for 25 minutes. Plasma
samples were kept on ice until they were assayed.
Plasma heparin levels were determined by the aPTT clotting
assay. A test tube containing 100 .d of activated cephalopiastin
reagent (Dade Diagnostic, Aguada, Puerto Rico) prewarmed to
37°C was incubated with 100 1d of the plasma sample for two
minutes and 100 pi of 0.02 M CaC12 was then added. After 25
seconds, a platinum innoculating loop was drawn manually
through the mixture until a clot formed and the time was
recorded. The assay was linear with heparin activities in the
range 0.0 to 0.7 U/mi. A standard curve was constructed for
each animal. Samples outside of the linear range were diluted
with normal plasma from the same animal. Each sample was
assayed in triplicate and the measurement error in heparin
activity was less than 3%. The heparin degradation products do
not possess any significant activity by the aPTT assay [17, 18].
The clearance of heparin, CH, was calculated as:
= Qb (C1 — C0)/C1
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where Qb was the blood flow to the filter, C1 was the activity of
heparin entering the filter and C0 was the activity of heparin
leaving the reactor.
Hematologic studies
At each time point, two 2 ml blood samples for cell counts
were drawn directly from the animal's arterial shunt (Point A,
Fig. 2). The animal's hematocrit, red cell counts, white cell
counts, platelet counts and total blood hemoglobin were mea-
sured. The blood was drawn in vacutainer tubes containing
EDTA (Becton Dickinson, Rockville, Maryland, USA) for
complete blood cell counts and in vacutainer tubes containing
sodium citrate (Becton Dickinson) for platelet counts. Samples
were drawn at the start and the end of the experiment for the
determination of the plasma—free hemoglobin levels.
White cell counts, red cell counts, total hemoglobin and
hematocrit were measured using a Coulter counter (Coulter
Electronics, Hialeah Florida, USA). Platelet counts were per-
formed manually using a light microscope (American Optics,
A-tb). White cell and red cell duplicates agreed within 2%
while platelet duplicates agreed within 15%. Plasma free hemo-
globin was measured using a benzidine colorimetric assay [26].
For each animal, the values were combined for the different
experiments and the mean profiles were analyzed. The cell
counts were normalized by the cell count at the start of the
experiment and plotted as percents. One way or two way
analyses of variance were utilized to analyze the data [27]. All
values are presented as the mean plus or minus the standard
deviation (sD).
Necropsy
The animals were euthanized with an injection of sodium
pentobarbitol (81 mg/kg) directly into the animals' arterial
shunt. The sheep were subjected to a complete necropsy with a
careful gross examination of all organs and tissues. Samples of
all major tissues—brain, oral cavity, thymus, heart, lung,
kidney, spleen, liver, representative segments of the GI tract,
urinary bladder—were taken. The tissue samples were fixed in
10% neutral buffered formalin, embedded in paraffin, cut at 4
m, and stained with hematoxylin and eosin for histological
evaluation according to standard procedures [28].
Results
Reactor design and development
The volume of immobilized heparinase, the concentration of
immobilized heparinase, the agarose content of the gel and the
minimum internal recirculation flow to maintain the reactor
contents well mixed were determined. Since this part of the
study was concerned only with reactor optimization, it was not
necessary to use the blood flow of 200 mllmin utilized for
hemodialysis. Unless otherwise stated, these preliminary stud-
ies were conducted at a blood flow of 120 mllmin and without a
dialyzer in the extracorporeal circuit.
Optimal agarose composition. The agarose matrix is avail-
able as spherical particles with diameters in the range 150 to 300
pm. The range of blood flows (120 to 200 mllmin) for the current
study is much higher than normally used for most applications
of agarose [29] subjecting the gel to larger than usual mechan-
Table 1. The initial and final diameters and the percent recovery of
agarose beads tested on line with a heparinase reactor connected to a
sheep
Agarose
% N
Initial
diameter
un
Final
diameter
p.m
Volume
beads
recovered %
4 4 70±5 50±4 50±4
6 3 80±6 65±5 90±6
8 8 110±6 109±6 98±4
10 6 112±7 114±5 98±3
The blood flow was 250 mI/mm and the length of the experiment was
1 hour. A total of 21 experiments with 6 animals was performed. The
data are presented as the mean SD.
ical forces. The potential for damaging the beads exists and
ways to increase strength of agarose were investigated.
We examined increasing the strength of agarose in two
independent ways: first by increasing the agarose content of the
gel and secondly by crosslinking the agarose with 2,3, dibro-
mopropanol. Studies were performed with crosslinked beads
with agarose contents ranging from 4% to 10% to determine the
minimum agarose content necessary to maintain the gel's
structural integrity and to prevent the gel from embolizing into
the animal.
Reactors primed with a known volume of beads were tested
in six animals for a total of 22 trials. At the end of the
experiment, both the volume and the size of the particles
remaining in the reactor were measured. The beads were
exposed to stresses greater than would be expected during the
normal operation of the reactor. This was accomplished by
operating the device at a blood flow of 250 mllmin which is the
highest attainable from the shunts without causing discomfort
to the animals.
The initial and final mean particle diameters of the different
agarose gels are summarized in Table 1. There was no change in
the mean particle diameter for the 8% and 10% beads while the
4% and 6% beads had a 25 to 35% drop in particle diameter. The
4% and 6% beads examined with the light microscope appeared
fragmented and had rough surfaces while the 8% and 10% did
not.
The recovery of the crosslinked beads from reactors tested ex
vivo in the sheep as a function of agarose content is summarized
in Table 1. No loss of agarose from the reactor was found as
long as the agarose content of the crosslinked gel was 8% or
higher.
Immobilization of heparinase. Heparinase was covalently
immobilized to different composition agarose gels preactivated
with cyanogen bromide. Before selecting the appropriate com-
position of agarose, a second study was conducted to determine
the effect of agarose content on the retention of enzymatic
activity after immobilization.
The fraction of heparinase activity retained as a function of
agarose content is shown in Table 2. There was no statistically
significant difference in the heparinase activity retained for the
four agarose concentrations. After immobilization, 43 6% (N
= 33) of the initial enzymatic activity was recovered.
Based on the fraction of heparinase activity retained and the
leakage of agarose from the reactor, both 8% and 10% agarose
were suitable for usage. The 8% agarose has more internal
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Agarose
% N
Activity recovered
%
4 15 45±8
6 2 40±7
8 8 40±7
10 8 43±7
surface area than the 10% gel and allows more heparinase to be
immobilized per support volume [29]. Thus all further studies
were conducted with an 8% crosslinked agarose matrix.
Determination of internal recirculation rate. The compress-
ible nature of agarose causes the gel to pack at high flows and
limits the blood flow through the reactor to less than 10 mi/mm
[29]. To increase the range of operating flows and to prevent
bead packing, the agarose was maintained in a fluidized state
using an external source of agitation. A recirculation line was
installed through the base of the device and was connected to a
peristaltic pump (Fig. 1). The pump continually circulated the
contents of the reactor and kept the system well mixed.
This configuration was tested in five sheep to determine the
optimal volume of agarose and the minimal recirculation rate
required to prevent bead packing in the reactor. Recirculation
flows between 570 and 1800 mI/mm and bead volumes of 50 to
125 ml were examined. Packing was quantified by the pressure
drop across the reactor and by visually inspecting the reactor
for macrociumps. A high degree of packing was correlated with
pressure drops across the reactor of greater than 50 mm Hg.
Clump formation within the reactor was eliminated as long as
the gel volume was 85 ml or less and the recirculation rate was
at least 1200 mllmin (N = 19).
Preliminary heparin removal studies. A study was conducted
to determine the concentration of immobilized heparinase nec-
essary to maintain the heparin level within the circuit two to
three times that in the animal. The reactor was tested on six
animals using a regional heparinization scheme for a total of 18
trials. The volume of beads in the reactor was maintained at 85
ml and immobilized heparinase concentrations in the range 25
to 200 U/mI were examined.
Two types of control experiments were conducted to deter-
mine the amount of heparin non-specifically removed from the
extracorporeal circuit. The control reactors contained either
plain agarose or agarose with heat inactivated immobilized
heparinase, Both types of control reactors resulted in less than
a 2% difference between the inlet and the outlet heparin
activity. This is on the same order as the measurement error for
heparin and thus non-specific removal of heparin was consid-
ered negligible. All decreases in heparin activity across the
reactor were thus attributed to enzymatic degradation.
A minimum heparinase concentration of 100 U/mi was nec-
essary to achieve heparin clearances greater than 10% of the
inlet flow to the reactor. The clearance of heparin by the reactor
was in the range 36 to 56 ml/min which was 27 to 47% of the
inlet flow (Fig. 3). The enzymatic activity of the reactor as
determined by the clearance of hepann decreased over the
course of the experiment. The results from all of the experi-
ments were combined and yielded a mean drop in heparin
clearance of 43 10% (N = 18). The heparin level in the circuit
was on the average 2.64 0.19 (N = 18) times greater than the
value in the animal (Fig. 4).
The pressure drop across the reactor remained constant with
time and was in the range 10 to 20 mm Hg for all of the
experiments. During each experiment, it was possible to visu-
alize directly, through the reactor housing, clumps of at least 3
mm in diameter. No clumps greater than 1 cm in diameter were
seen during the operation of the reactor. At the end of the
experiments, microthrombi were seen in approximately one—
third of the reactors after the blood had been washed out. These
microthrombi were examined with a light microscope and
Table 2. The effect of agarose content on the fraction of heparinase
activity retained after covalent immobilization to cyanogen bromide
activated agarose
The data are presented as the mean SD
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Fig. 3. The clearance of heparin by the heparinase filter at a blood flow
of 120 mI/mm. Each point is the mean of 18 experiments involving 6
animals and the data are plotted as the mean SD.
6
4
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0 I I I
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Fig. 4. The plasma concentration of heparin in the extracorporeal
circuit and in the animal as a function of time. The blood flow to the
reactor was 120 ml/min. Each point is the mean of 18 experiments
involving 6 animals and the data are plotted as the mean SD. Symbols
are: (U) extracorporeal circuit; () animal.
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Fig. 5. The effect of the heparinase reactor on formed blood elements
at a blood flow of 120 mI/mm. All data are plotted as percent of the
initial value. Each point is the mean of 18 experiments involving 6
animals and the data are plotted as the mean SD. A. Red cell counts.
B. Platelet counts. C. White cell counts.
revealed fibrin strands intertwined with blood cells and three to
four agarose beads.
Reactor hemocompatibility. The effects of the heparinase
reactor on platelet counts, red cell counts, white cell counts,
hematocrit, total blood hemoglobin and plasma—free plasma
hemoglobin were determined. The variability between different
animals was not statistically significant and the mean profiles
are now presented.
The red cells fluctuated between 100% and 94% over the one
hour experiment (Fig. 5A). The change in red cell counts with
time was not statistically significant and thus the red cell counts
remained constant with time.
The platelet counts declined continuously with time (Fig.
5B). The decrease in platelet counts was statistically significant
(P < 0.005) with a mean value of 53 10% (N = 18) after one
hour.
The white cell counts dropped rapidly within the first 20
minutes of the experiment after which the counts began to
rebound (Fig. SC). The transient decrease in white cell counts
was statistically significant (P < 0.001). The white cell counts
Time, mm
Fig. 6. The effect of 'he heparinase reactor on the total blood hemo-
globin and hematocrit at a bloodflow of 120 mI/mm. All data are plotted
as percent of the initial value. Each point is the mean of 18 experiments
involving 6 animals and the data are plotted as the mean SD. A.
Hematocnt. B. Total hemoglobin.
dropped to a value of 43 9% (N 18) at 20 minutes and
returned to a final value of 78 9% (N 18).
The normalized hematocrit varied between 100% and 95%
over the course of the experiment which was not statistically
significant (Fig. 6A). The total hemoglobin remained constant
with time (Fig. 6B). The initial plasma—free hemoglobin con-
centration was negligible. At the end of the one hour experi-
ment, the plasma free hemoglobin had increased to 88 35
mg/dI (N = 18) which was less than 1% of the total blood
hemoglobin.
All three cell counts returned to their baseline values 24 hours
after the experiment.
Source of blood damage. A study was conducted to deter-
mine whether the decreases in the white cells and the platelets
were due to the mixing characteristics within the reactor, the
agarose matrix or the immobilized heparinase. Four different
groups of reactors were studied ex vivo in sheep. The first
reactor type was empty, the second contained plain 8% cross-
linked agarose, the third contained 8% crosslinked agarose with
heat inactivated immobilized heparinase and the last contained
active immobilized heparinase. The volume of beads, the blood
flow, the internal recirculation rate, and the heparin infusion
rate were all maintained at the values used previously. A single
animal was used for all experiments to eliminate any animal to
animal variability. Between experiments, the animal was rested
for two days.
There was no statistically significant difference between
having an empty reactor or including the three different types of
agarose on the animal's red blood cell levels. The individual red
cell proffles are shown in Figure 7A.
Similiarly, there was no statistically significant difference
between having an empty reactor or including the three dii-
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Fig. 7. The effect of the filter contents on the formed blood elements at
a blood flow of 120 mi/mm. Each point is the mean of two experiments
and the data are plotted as the mean SD. The same animal was used
for all experiments. A. Red cell counts. B. Platelet counts. C. White cell
counts. Symbols are: (0) empty filter, () filter with plain agarose, (K')
filter with heat inactivated immobilized heparinase, (0) filter with active
immobilized heparinase.
ferent types of agarose on the animal's platelet counts. The
individual profiles are shown in Figure 7B. The change in the
counts with time was statistically significant (P < 0.005) drop-
ping to 55 11% (N = 8).
The animal's white cell counts for each reactor type as a
function of time are shown in Figure 7C. For the reactor
without beads, there was no statistically significant drop in
white cell count. The changes in the white cell counts with time
were statistically significant for the three reactor sets containing
the different types of agarose (P < 0.001). For each reactor
type, the white cell counts declined in the first twenty minutes
after which they started to rebound. Both the values attained at
twenty minutes and at the end of the experiment were different
depending on the reactor.
Filter testing for hemodialysis
Heparin removal studies. The heparinase reactor was tested
with a dialyzer as illustrated in Figure 2. Based on the results of
the preliminary testing, 85 ml of immobilized heparinase and
heparinase concentrations in the range 100 to 200 U/ml were
used. The blood flow was increased to 200 mllmin and the
heparin infusion rate was increased from 10000 to 18000 U/hr
because of the large surface area (1.5 m2) of the dialyzer. Five
animals were used for this study for a total of 16 trials.
The clearance of heparin by the heparinase reactor is shown
in Figure 8. Even though the flow was increased to 200 mllmin,
the clearance of heparin by the reactor was in the range 50 to 70
mI/mm which was 25 to 35% of the inlet flow. The enzymatic
activity of the reactor as determined by the clearance of heparin
decreased over the course of the experiment. The results from
all of the experiments were averaged and yielded a mean drop
in heparin clearance of 32 5% (N = 16) after one hour.
The activities of heparin in the animal and the extracorporeal
circuit are given in Figure 9. The ratio of the heparin activity in
the extracorporeal circuit to the animal's plasma heparin activ-
ity was maintained at an average value of 2.77 0.22 over one
hour.
The pressure drop across the reactor remained constant with
time and was in the range 10 to 20 mm Hg for all the
experiments. No clumps greater than 1 cm in diameter were
seen during the operation of the reactor. Occasional micro-
thrombi were seen in the reactor at the end of some experiments
after the blood had been washed out. These microthrombi were
similiar to those found in the previous experiments.
Reactor hemocompatibility. The effects of both the dialyzer
and the heparinase reactor on the animal's platelet counts, red
cell counts, white cell counts, heniatocrit, total blood hemoglo-
bin and plasma free hemoglobin were determined. To separate
the effects of the heparinase reactor from those of the dialyzer,
control circuits containing only the hemodialyzer were tested.
For both the control and the extracorporeal circuit with the
heparinase reactor, the red cells fluctuated between 100% and
95% (Figure bA). Both the changes in the red cell counts with
time as well the differences between the two circuits were not
statistically significant. Thus the hemodialyzer or the hemodi-
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Fig. 8. The clearance of heparin by the heparinase filter on line with a
hemodialyzer at a blood flow of 200 mI/mm. Each point is the mean of
16 experiments involving 6 animals and the data are plotted as the mean
SD.
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Time, rn/n
Fig. 9. The plasma concentration of heparin in the extracorporea!
circuit (hemodialyzer and heparinase reactor) and in the animal as a
function oft/me. The blood flow to the reactor was 200 mi/mm. Each
point is the mean of 16 experiments involving 6 animals and the data are
plotted as the mean SD. Symbols are: (D) extracorporeal circuit, (A)
animal.
alyzer in series with the reactor had no effect on the red cell
counts.
The platelet counts declined continuously with time in both
the control and the experimental circuits (Figure lOB). The
decrease in platelet counts was statistically significant (P <
0.001) for both circuits. After one hour, the dialyzer alone
resulted in a drop in platelets of 25 3% (N = 6) while the
hemodialyzer coupled with the heparinase reactor led to a total
drop of 45 8% (N = 16).
For both extracorporeal circuits, the white cell counts dropped
rapidly within the first 20 minutes of the experiment after which
the counts began to rebound (Figure 1OC). The drop and
rebound in white cell counts were statistically significant for
both circuits (P < 0.001). With only the hemodialyzer, the white
cell counts dropped to a value of 50 7% (N = 6) at 20 minutes
and returned to a final value of 88 7% (N = 6) at 60 minutes.
When the heparinase reactor was included in the circuit, the
white cell counts were 47 7% (N = 16) and 72 10% (N = 16)
at 20 and 60 minutes, respectively. Only the values at 60
minutes were significantly different between the two circuits (P
<0.001).
The mean hematocrit profiles for both circuits are shown in
Figure 1 1A. The normalized hematocrits varied between 100%
and 95% over the course of the experiments. Both these
fluctuations and the differences between the two different
circuit types were not statistically significant.
The total blood hemoglobin for the control and the circuit
with the heparinase reactor are shown in Figure 1 lB. The
differences between the two circuits were not statistically
significant and both remained constant with time. The initial
plasma free hemoglobin levels for both circuits were negligible.
The plasma free hemoglobin after one hour was 87 15 mg/dl(N = 6) and 89 33 mg/dl (N = 16) for the control and
experimental circuits, respectively. The plasma free hemoglo-
Time, rn/n
Fig. 10. The effect of the heparinase reactor on formed blood elements
at a blood flow of 200 mI/mm. All data are plotted as percent of the
initial value. Each point is the mean of 16 experiments involving 6
animals and the data are plotted as the mean SD. A. Red cell counts.
B. Platelet counts. C. White cell counts. Symbols are: (D) dialyzer
alone, (A) dialyzer + heparinase reactor.
bin concentration in both circuits was less than 1% of the total
blood hemoglobin.
All three cell counts returned to their baseline values 24 hours
after the experiment.
Chronic exposure. Two animals were exposed to the hepa-
rinase reactor with hemodialysis once or twice a week for a
period of 10 weeks and a total of 16 experiments per animal. At
the end of this period the animals were sacrificed and a
complete autopsy performed. No abnormalities were found in
the major organ systems upon gross examination. A histological
examination showed no visible lesions or chronic inflammation
in the organ systems examined.
Experiments conducted at the start and finish of the 10 week
experimental period were compared to see if there were any
changes with chronic use in both the effectiveness of the filter
and the animal's hematological status. Reactors containing the
same gel volume and immobilized enzyme concentration were
compared. The clearances for both animals are shown in Figure
12. There was no statistically significant difference between the
initial and the 10 week clearance. Similarly, there was no
significant difference between the initial and 10 week platelet
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Fig. 11. The effect of the heparinase reactor on the total blood
hemoglobin and hematocrit at a blood flow of 200 mI/mitt. All data are
plotted as percent of the initial value, Each point is the mean of 16
experiments involving 6 animals and the data are plotted as the mean
SD. A. Hematocrit. B. Total hemoglobin. Symbols are: (0) dialyzer
alone, () dialyzer and heparinase reactor.
counts, red cell counts, white cell counts, hematocrit, total
blood hemoglobin and plasma free hemoglobin.
Discussion
The heparinase reactor was a conventional blood filter that
had been modified to include a recirculation line connected to a
peristaltic pump. The recirculation line served as an external
source of agitation and allowed the heparinase—agarose to be
maintained in a fluidized state. This prevented the agarose from
packing and permitted blood flows up to 250 ml/min through the
heparinase filter.
Fracturing of the agarose matrix with resultant leakage from
the device was prevented as long as the agarose content of the
matrix was at least 8% and the gel was crosslinked with 2,3,
dibromopropanol. This was determined by measuring the vol-
ume of agarose remaining in the device at the end of the
experiment. Future studies involving the reactor will employ an
ultrasonic microaggregate detection system [301 to verify the
above findings.
The fractional clearance of heparin (that is, the ratio of the
heparin clearance to the inlet flow) was greater at the lower flow
(120 mllmin). However, the absolute clearance of heparin was
greater at the higher flow (200 mI/mm). These values are
summarized in Table 3. The lower flow is commonly used for
continuous arteriovenous hemofiltration [31] while the higher
flow is used for hemodialysis [21. Thus the reactor may be of
value for either of these applications.
Table 3. The effect of flow on the clearance of heparin by the
heparinase filter
Fractional
Flowrate
mt/mitt N
Clearan
Initial
ce mI/mitt
Final
clearance %
Initial Final
120 18 56 36 47 27
200 16 70 50 35 25
Both the absolute clearance and the clearance normalized by the flow
to the device are given. The values at the start and the end of the
experiment are shown.
The use of the heparinase reactor in conjunction with a
regional heparinization scheme permitted the heparin activity in
the extracorporeal circuit to be maintained at a higher level than
in vivo. The heparin activity in the circuit was maintained at
2.64 to 2.77 times the level in the animal. This is ideally suited
for both continuous arteriovenous hemofiltration and hemodi-
alysis. In some clinical settings, the heparin activity cannot be
increased to levels sufficient to prevent partial clotting of the
devices because of the increased liklihood of severe hemor-
rhagic complications [2]. The use of the heparinase reactor in
series with these extracorporeal devices permits the usage of
higher heparin doses in the circuit.
After one hour, the heparin clearance dropped to 57% and
65% of the initial clearance at 120 ml!min and 200 mI/mm,
respectively. The accumulation of blood proteins on the sur-
faces of the beads preventing heparin from permeating the
agarose, the formation of bead microaggregates with a net
decrease in accessible enzyme, and heparinase deactivation due
to thermal effects are potential causes for the transient drop in
the heparin clearance.
At both flows, the invariance of the animal's red cell counts,
hematocrit, total blood hemoglobin and the plasma free hemo-
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60 — — Fig. 12. The effect of chronic exposure to the heparinase filter on theB ( clearance of heparin. Each animal underwent 16 treatments over a ten
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Table 4. The effect of flow on the white cell counts at 20 and 60
minutes
Flowrate
mi/mm Extracorporeal circuit
White cell counts %
20 minutes 60 minutes
120 Reactor only (N = 18)(N = 16)
43 9 78 8
200 Hemodialyzer only (N = 6) 50 7 88 6
200 Hemodialyzer and reactor 47 7 72 10
The counts are presented as percent of the initial value and given as
the mean SD.
globin being less than 1% of the total blood hemoglobin suggest
that hemolysis is negligible. The plasma free hemoglobin after
one hour was 87 mg/dl and 89 mg/dl for the control and
experimental circuits, respectively. These values are greater
than the normal upper limit of 5.7 mg/dl seen in man [32]. The
difference in plasma free hemoglobin between the hemodialyzer
alone and the hemodialyzer with the reactor was not statisti-
cally significant. Thus the heparinase reactor did not cause any
further elevation in hemoglobin levels compared with the
hemodialyzer alone.
After one hour, the platelet counts decreased to 53% and 55%
of their initial values at flows of 120 and 200 ml/min, respec-
tively. These changes in platelet counts were comparable to the
40 to 65% drops that have been previously observed in sheep
undergoing extracorporeal therapy [33—35]. The drop in platelet
counts did not seem to be caused by the agarose gel or the
immobilized heparinase since an empty reactor resulted in the
same drop in c -)unts as a non-empty reactor. This suggests the
platelet damage caused by the heparinase reactor ex vivo was
due to the mixing properties within the device.
The difference between the final platelet counts at the two
flows was not statistically significant even though at the higher
flow the circuit contained both the dialyzer and the reactor. One
explanation for the lack of a significant increase in platelet loss
with two devices in the circuit may relate to the residence time
within the reactor. At the low flow a single pass through the
device requires 2.0 minutes while at the high flow only 1.25
minutes is required. Thus the presence of both the reactor and
the dialyzer may be offset by the shorter time spent within the
circuit.
The white cell counts dropped rapidly within the first 20
minutes of the experiment after which the counts began to
rebound. The values reached at both 20 and 60 minutes are
summarized in Table 4. The heparinase reactor in series with
the hemodialyzer caused no further drop in white cell counts as
compared with the hemodialyzer alone. However, the white
cells rebounded to only 73% in the complete circuit whereas a
value of 88% was attained for the dialyzer alone (P < 0.001).
A transient drop in white blood cells has been consistently
observed in both humans and animals undergoing dialysis
[36—38]. This phenomenon has been linked to the activation of
the plasma complement system [36—38]. This may cause a
transient sequestration of the white cells in the lungs and the
spleen and a drop in circulating levels. The effect is temporary
and the gradual release of the white cells into the circulation is
responsible for the observed rebound [36—38].
The drop in white cell counts was not caused by the agitation
within the device since an empty reactor with recirculation
resulted in no statistically significant change in cell counts.
However, the presence of agarose with and without immobi-
lized enzyme caused a drop in the white cell numbers (Fig. 7).
The variable response of the white cells to the different reactor
contents may be due to differing degrees to which the comple-
ment system is activated. The smaller drop for the reactor with
active heparinase may be related to the inhibition of comple-
ment activation by the heparin degradation products [39, 40].
One concern was that the continuous exposure of the animals
to the heparinase reactor might lead to an endogenous response
to neutralize the enzymatic activity of the device. However, the
performance of the reactor did not decrease with repeated use
over the 10 week period nor were there any chronic changes in
the response of the animal's formed blood elements to the filter
during this time period. Despite the less than 1% hemolysis at
the end of each treatment as determined by the rise in plasma
free hemoglobin, the animals did not become anemic after 10
weeks. We do not know whether anemia would develop in
uremic sheep.
Prior studies have addressed certain aspects of the toxicology
of heparin breakdown products. It was shown that the heparin
degradation products are not cytotoxic or mutagenic at levels
100 times higher than the animals in this study were exposed to
[16]. The degradation products were removed five times more
rapidly than the parent compound heparin in normal and
nephrectomized rats with no buildup of the products in any of
20 different organ systems studied at doses comparable to the
current study [181. Furthermore none of these organs showed
any detectable pathologic changes when exposed to these
products [41].
A total of 24 sheep and 75 experiments were used to optimize
and test the device. The length of each treatment was kept to
one hour as opposed to the usual four hour dialysis treatment.
In this way it was possible to test the device on unanesthetized
sheep. Given the large number of animals and experiments
needed to develop and test the device, the elimination of
anesthesia maximized the number of experiments that could be
conducted on each animal. Furthermore, future studies will
concentrate on stabilizing the enzymatic activity of immobilized
heparinase in order to maintain a more constant heparin clear-
ance and so that the filter could be effectively operated over a
four hour treatment time. Techniques such as glutaraldehyde
crosslinking or chemical modification of enzymes have been
successfully applied to stablilize several enzyme systems [42—
44] and will be applied to heparinase.
The coupling of proteins to cyanogen bromide activated
agarose is via a reversible isourea linkage [241. The detachment
rate of immobilized heparinase in blood is currently under study
using an iodinated enzyme preparation. If the leakage rate is
significant, alternate coupling procedures such as tresyl chlo-
ride or epoxides will be tried [45, 46]. The extent to which
complement is activated during the treatment period as well as
antibody formation with chronic use should be determined.
The significance of this heparinase filter is that it may open
new possibilities in extracorporeal treatment. One of the advan-
tages is the opportunity of anticoagulating the extracorporeal
system with higher heparin activities, thus reducing early
occlusion of the hemofiltration devices. The generality of such
a filter would enable it to be used in a variety of situations where
heparin removal or reduction is required. In addition to poten-
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tially making possible a new approach to hepann therapy, these
studies provide support for the feasibility of using other immo-
bilized enzymes and antibodies in medical studies. The reactor
lends itself to the processing of whole blood and not just plasma
as in several other systems [47, 48]. This reactor could ideally
be applied to any enzyme or antibody system and hopefully will
contribute to the development of new toxin removal systems.
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